Prior authorization required for home enteral nutrition when selection criteria apply

Certain home enteral nutrition and enteral formula HCPCS codes are covered if selection criteria are met and may require prior authorization under this policy; providers should obtain prior authorization when billing codes such as S9340–S9343, B4034–B4036, B4102–B4162, and B9002 are used for home enteral nutrition services.

• HCPCS codes referenced: S9340–S9343, B4034–B4036, B4102–B4103, B4149–B4162, B9002

Use listed CPT/HCPCS device and procedure codes and note coverage designations

The policy lists specific CPT/HCPCS codes for device-based and neurostimulation procedures and notes some codes are designated not covered for the indications in this CPB; use the listed codes when requesting authorization and beware of not‑covered designations.

• Device/neurostimulator codes cited include 95970–95976, 95983–95984, 96020 and HCPCS C1767, C1778, C1816, C1883, C1897, E0745, L8680–L8689, L8695.
• HCPCS enteral/home nutrition codes are listed separately (see enteral nutrition section).

Prior authorization and detailed clinical data required for DBS and other invasive experimental procedures

Invasive or experimental procedures such as deep brain stimulation (DBS) generally require prior authorization with submission of patient‑level data demonstrating treatment‑refractory status, prior therapies tried, and rationale for the chosen stimulation target.

• DBS described as experimental/under study; systematic reviews included patient‑level data and highlighted safety/adverse event concerns and small sample sizes.
• Prior authorization should include documentation of prior attempts and rationale for DBS target selection.

Background evidence summaries do not substitute for prior‑authorization rules

Background and evidence summary sections do not by themselves state specific prior authorization requirements; they summarize evidence that may inform coverage determinations but do not replace administrative PA rules.

• Evidence summaries in background may influence but do not specify PA code or process.
• Administrative prior‑authorization requirements are addressed elsewhere in the policy.

Prior authorization likely required for investigational interventions (relamorelin, ION™, Mandometer)

Interventions characterized as investigational or with insufficient evidence (for example, relamorelin, the ION™ panel, and the Mandometer residential program) may require prior authorization with supporting clinical rationale and documented trial data before coverage is considered.

• Relamorelin (ghrelin agonist) studied in small RCTs; long‑term safety/efficacy not established.
• ION™ analysis/profile lacks evidence of clinical value.
• Mandometer residential program clinical value not established; may be considered investigational.

Require prior authorization and clinical rationale for novel neuromodulation

Novel neuromodulation treatments (multi‑session rTMS, tDCS, and similar) remain investigational with mixed evidence; prior authorization should require documentation of rationale, informed consent, and evidence of prior standard therapies.

• Multi‑session rTMS/tDCS evidence is preliminary and mixed; excitatory NIBS in anorexia may be contraindicated.
• PA should document prior attempts at nutritional rehabilitation and evidence‑based psychotherapy, rationale for neuromodulation, and monitoring plans.

Prior authorization must justify TMS as adjunctive/experimental therapy

When TMS is considered for eating disorders it should be treated as adjunctive/experimental; prior authorization should request justification that TMS is being used as adjunctive treatment and documentation of failure or intolerance of established treatments, plus a monitoring plan for outcomes and adverse events.

• Guidelines state TMS is not an established treatment and should not replace nutritional rehabilitation or evidence‑based psychotherapy.
• PA should include prior treatment history, rationale for TMS, stimulation protocol/site, and monitoring plan.

No specific PA codes listed in this excerpt — follow plan PA processes

This administrative excerpt does not state specific prior authorization code requirements; providers should follow plan‑level PA processes and use the policy’s listed codes when applicable.

• The CPB is an administrative aid and does not list a separate PA code table in this excerpt.
• Follow member plan provisions and Aetna PA procedures for submission.

No explicit step‑therapy algorithm provided in this excerpt

No explicit step‑therapy algorithm is specified in this portion of the document; the policy does not define a formal step‑through sequence here.

Document sequencing: pharmacotherapy is adjunctive (fluoxetine for BN; lisdexamfetamine for BED)

Pharmacotherapy is described as adjunctive to nutritional rehabilitation and psychotherapy; fluoxetine is recommended for bulimia nervosa (e.g., 60 mg) and lisdexamfetamine is an FDA‑approved option for binge‑eating disorder.

• Fluoxetine recommended for BN (60 mg daily) as first‑line pharmacotherapy.
• Lisdexamfetamine is an option for BED; medications are adjunctive and not first‑line for AN.

CBT is guideline‑preferred first‑line psychotherapy before alternatives

Practice guidelines and major reviews recommend CBT as first‑line psychotherapy for bulimia and BED; payers may expect a trial of CBT before covering adjunctive or alternative psychotherapies in many cases.

• DBT is considered adjunctive/alternative and has not shown superiority to CBT in systematic reviews; CBT remains first‑line.
• Document trials of CBT when seeking coverage for alternative psychotherapies.

No step‑therapy rules described; ghrelin agonists are investigational

No formal step‑therapy requirements are described in these background sections; ghrelin agonists and similar agents are noted as investigational and lack sufficient evidence to define sequencing rules.

• Ghrelin administration did not significantly affect appetite in a small trial and relamorelin has limited short‑term data.
• No step‑therapy sequencing is specified for these agents in the excerpt.

No step‑therapy rules specified in background sections

Background sections do not specify step‑therapy rules; the document states no formal step‑therapy algorithms are provided in this excerpt.

Require trial of lower‑intensity interventions (guided self‑help/psychotherapy) before higher‑intensity BED treatments

For BED, evidence supports guided self‑help and certain pharmacotherapies; consider requiring trials of lower‑intensity guided self‑help or psychotherapy before authorizing higher‑intensity pharmacotherapy or surgical interventions.

• Guided self‑help showed benefit for BED in referred populations.
• Lisdexamfetamine and topiramate reduced BED symptom severity but have associated harms and require monitoring.

Neuromodulation only after optimization of nutrition and evidence‑based psychotherapies

Neuromodulation (including TMS) should be considered only after optimization of nutritional rehabilitation and evidence‑based psychotherapies; documentation of prior optimization is expected when seeking authorization.

• Guidelines emphasize TMS should not replace nutritional rehabilitation or evidence‑based psychotherapy.
• PA/authorization should show attempts to optimize nutrition and psychotherapy prior to neuromodulation.

No formal step‑therapy protocol specified in this excerpt

Reiterating the document’s content, no formal step‑therapy protocol is specified within this excerpt; providers must follow plan‑specific step rules if present elsewhere.

Document complete medical evaluation and recommended laboratory testing

Clinical documentation must include a complete medical history and physical examination and relevant laboratory testing (e.g., CBC, electrolytes, liver function tests, TSH, ECG) when managing anorexia nervosa or bulimia nervosa.

• Document CBC and comprehensive metabolic panel including electrolytes, liver and renal tests.
• Obtain ECG for restrictive disorders, severe purging, or QTc‑prolonging medications.

Document comprehensive initial psychiatric and physical evaluation including height/weight history

Initial psychiatric and physical evaluations should document height/weight history, patterns of restrictive and binge/purge behaviors, compensatory behaviors, psychosocial impairment, prior treatment response, and a comprehensive review of systems as part of the initial workup.

• Record maximum/minimum weight, recent weight changes, and quantify eating/weight control behaviors.
• Identify co‑occurring psychiatric and medical conditions and include a comprehensive review of systems.

Document indication, malnutrition evidence, feeding method and monitoring for enteral nutrition

For enteral nutrition (nasogastric feeding) document the indication for weight restoration, evidence of malnutrition or refractory oral intake, details of the feeding method and monitoring (including prophylactic electrolyte/phosphate supplementation where used), and whether care is inpatient versus outpatient.

• Document objective evidence of inadequate oral intake and weight restoration goals.
• Include details of NG feeding method, monitoring plans, and any prophylactic electrolyte management.

Provide clear clinical rationale and document study limitations when using limited‑evidence interventions

When submitting evidence or studies for limited‑evidence interventions, note methodological limitations (small samples, lack of dietary control, female‑only cohorts); include a clear clinical rationale tied to member‑level data when using such interventions.

• Describe study limitations if relying on literature to support coverage requests.
• Provide member‑specific clinical justification beyond limited studies.

Document baseline diagnosis, BMI, gastric emptying testing, and monitoring for ghrelin agonist use

For trials or off‑label use of ghrelin agonists (e.g., relamorelin) document DSM‑5 diagnosis, baseline weight/BMI, gastric emptying testing if used (GEBT), and monitoring of weight change and adverse effects during treatment.

• Include baseline BMI and GEBT results when used to support relamorelin use.
• Monitor and record weight change and any adverse events during therapy.

Document diagnosis, setting, outcomes, and concurrent treatments for I‑ERP programs

For I‑ERP programs record the diagnosis, treatment setting (inpatient vs outpatient), concurrent treatments, pre‑ and post‑intervention outcome measures (e.g., EDE‑Q, anxiety/depression scales), and follow‑up plans.

• Document outcome measures and follow‑up; note that existing I‑ERP evidence is pilot‑level and often adjunctive to inpatient care.
• Specify program structure and concurrent therapies.

Document prior trials and monitor adverse effects for BED pharmacotherapies

When using pharmacotherapies for BED (e.g., lisdexamfetamine or topiramate), document prior trials, rationale for selection, and actively monitor for known adverse effects (dry mouth, headache, insomnia for lisdexamfetamine; paresthesia, taste perversion, confusion for topiramate).

• Record prior psychotherapy/guided self‑help trials and justify medication initiation.
• Monitor and document adverse effects reported in RCTs.

Document rationale, stimulation parameters, and monitoring when using TMS/neuromodulation

Clinical documentation for neuromodulation (including TMS) should state that TMS is being used adjunctively/experimentally, include the rationale and targeted symptoms, specify stimulation site/protocol and parameters, and describe plans for monitoring adverse events and outcomes.

• Include stimulation protocol, site (e.g., dorsolateral prefrontal cortex), session duration and frequency.
• Document informed consent and plan for outcome monitoring and adverse event surveillance.

Providers must follow plan provisions and monitor CPB updates

Treating providers are responsible for medical advice and treatment of members; Clinical Policy Bulletins may be updated and are a partial description of plan benefits—verify plan provisions and follow any updated CPB guidance.

• CPBs do not constitute a contract; coverage outcomes are determined by plan provisions.
• Providers must follow current CPB updates and member benefit details.

Denial risk when billing codes for experimental/unproven services

Use of CPT/HCPCS codes for services explicitly listed as experimental/investigational or not covered (for example brain imaging, EEG, rTMS, ECT, fecal microbiota procedures, certain molecular/genetic tests) may trigger claim denials; verify coverage status before billing.

• Examples of codes/services at risk: brain imaging (70450–70553), EEG, 90867–90869 (TMS) and 90870 (ECT), 81403 (molecular pathology).
• Confirm coverage or obtain PA and provide supporting clinical documentation to mitigate denial risk.

Device/neurostimulator codes and certain ICD‑10 ranges are designated not covered for CPB indications

Specific HCPCS/CPT device and implantable neurostimulator codes and related ICD‑10 ranges are listed as not covered for indications in this CPB; billing these codes for the listed eating‑disorder indications risks denial unless an approved exception/PA is obtained.

• HCPCS device codes not covered include C1767, C1778, C1816, C1883, C1897, E0745, L8680–L8689, L8695.
• ICD‑10 ranges cited as not covered for CPB indications include F50.00–F50.029 and F50.20–F50.25.

DBS for anorexia nervosa has limited evidence and safety concerns—denial risk without strong documentation

Deep brain stimulation for anorexia nervosa is experimental and studied in small cohorts with reported adverse events (including a serious seizure); limited randomized data and safety concerns may lead to medical necessity denials or requests for additional documentation.

• DBS studies pooled 36 patients across 11 studies; adverse events included a seizure and other surgical complications.
• Provide robust patient‑level evidence of refractory illness and justification to avoid denial.

Background evidence summaries do not mandate specific authorization actions

Background sections do not mandate specific authorization actions; they summarize evidence and research gaps that may inform but do not dictate coverage or PA outcomes.

ION™ nutritional profiling lacks evidence—coverage may be denied as unproven

The ION™ (Individual Optimal Nutrition) analysis/profile lacks evidence of clinical value in eating disorders; ordering or billing for this panel without supporting evidence may be at risk for denial as medically unproven.

• ION™ measures multiple blood and urine nutritional markers but clinical utility in EDs is unproven.
• Provide strong clinical justification and prior evidence if requesting coverage.

Mandometer residential program is investigational—coverage may be denied without strong evidence

The Mandometer residential program is investigational with insufficient well‑designed comparative trials to establish clinical value; coverage may be denied absent strong comparative evidence and clear medical necessity.

• Program duration and remission claims derive largely from non‑randomized or small studies; randomized evidence is limited.
• Document comparative benefit and clinical necessity when requesting coverage for residential Mandometer treatment.

Residential/PHP continued‑stay coverage may be limited by lack of long‑term controlled evidence

Residential and PHP settings show short‑term improvements at discharge but lack controlled long‑term trial evidence and have high loss to follow‑up; continued‑stay or ongoing coverage decisions should document objective clinical response and nutritional markers.

• Few controlled long‑term outcome studies exist; document response at discharge and objective markers to support continued coverage.
• High drop‑out rates in studies complicate long‑term benefit claims.

Using TMS outside established indications requires clear justification to avoid denial

TMS is described as experimental/adjunctive and not an established treatment for eating disorders; use of TMS outside established indications should be justified in the medical record to reduce denial risk.

• Guidelines advise TMS should not replace nutritional rehabilitation or evidence‑based psychotherapy.
• Document rationale, prior therapy failures, and monitoring plans when using TMS.

CPBs are administrative guides; final coverage is determined by plan provisions

Clinical Policy Bulletins assist in administering plan benefits and provide only a partial description of benefits; coverage determinations are made according to the member's plan provisions and are not guaranteed by the CPB.